◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › IPSC

Century Therapeutics, Inc. (IPSC) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

Century Therapeutics, Inc. (IPSC) operates in the Biotechnology industry and is headquartered in Philadelphia, United States with about 78 employees. Its market capitalization is roughly $406 million. In the fiscal year ended 2025-12-31, IPSC reported $109M in revenue and ($10M) in net income.

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.

Interactive charts & full statements →

IPSC Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$109M$7M$2M$5M
Operating Income (EBIT)($10M)($134M)($125M)($124M)
Net Income($10M)($127M)($137M)($131M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IPSC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$109M
Operating Income (EBIT)($24M)($21M)($29M)($35M)$74M
Net Income($22M)($19M)($34M)($32M)$77M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IPSC Free Cash Flow History

IPSC Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$224M$353M$361M$486M
Total Liabilities$65M$192M$176M$184M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IPSC viewer.

Other Companies in Biotechnology

← IPMAll stocksIPST →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.